A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 19, 2015

Primary Completion Date

February 25, 2019

Study Completion Date

May 7, 2020

Conditions
Advanced Cancer
Interventions
DRUG

BMS-986148

BIOLOGICAL

Nivolumab

Trial Locations (17)

1200

Local Institution - 0009, Brussels

2170

Local Institution - 0013, Liverpool

3168

Local Institution - 0004, Clayton

5000

Local Institution - 0014, Adelaide

6009

Local Institution - 0015, Nedlands

9000

Local Institution - 0008, Ghent

20089

Local Institution - 0016, Rozzano (milano)

20133

Local Institution - 0018, Milan

20141

Local Institution - 0017, Milan

27710

Duke University Medical Center, Durham

92093-0698

Moores Cancer Center, La Jolla

T6G 1Z2

Local Institution - 0002, Edmonton

M5G 1Z5

Local Institution - 0003, Toronto

1066 CX

Local Institution - 0010, Amsterdam

3015 AA

Local Institution - 0011, Rotterdam

SO16 6YD

Local Institution - 0007, Southampton

G12 0YN

Local Institution - 0006, Glasgow

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY